INVO Fertility (IVF) AI Stock Analysis

• Market Cap: $1.94M
• Dividend Yield: N/A
• Average Volume (3M): 8.28M
• Price to Earnings (P/E): ―
• Beta (1Y): 0.17
• Revenue Growth: 11.50%
• EPS Growth: 2.37%
• Country: US
• Employees: 30
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): -6.16
• Shares Outstanding: 2,386,826
• 10 Day Avg. Volume: 24,408,967
• 30 Day Avg. Volume: 8,279,900
• PEG Ratio: >-0.01
• Price to Book (P/B): 0.24
• Price to Sales (P/S): 0.46
• P/FCF Ratio: -0.95
• Enterprise Value/Market Cap: 9.15
• Enterprise Value/Revenue: 2.56
• Enterprise Value/Gross Profit: 6.52
• Enterprise Value/Ebitda: -0.73
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 41 Neutral
• Price Target: $0.78 ▼(-16.67% Downside)

The score is held down primarily by weak financial performance (ongoing losses, margin compression, and negative operating/free cash flow) and a still-bearish technical setup (below key moving averages with negative MACD). Corporate events are a modest positive due to financing and expansion steps, but valuation is constrained by a negative P/E and no dividend support.

Positive Factors

Clinic acquisition growth strategy

Acquiring an established clinic with $1.2M trailing revenue directly expands INVO’s service footprint and patient base. The deal brings local management continuity and accelerates network scale, which can drive incremental referral flows, utilization gains, and clinic-level operating leverage over the next several quarters.

Leadership realignment to support scaling and M&A

Internal promotion preserves finance continuity while reassigning an experienced executive to lead acquisitions and clinic expansion. This structural change aligns management capabilities to execution needs, improving prospect of disciplined M&A integration and faster clinic rollouts over the medium term.

Improving leverage management

A lower, improving debt-to-equity ratio enhances balance-sheet flexibility to fund strategic initiatives and absorb acquisition-related costs. Reduced leverage risk provides durability to pursue inorganic growth without immediately overburdening cash flow, supporting medium-term financial stability if profitability improves.

Negative Factors

Deteriorating gross margins and persistent losses

A dramatic gross margin decline signals rising direct costs or pricing pressure that materially erodes core profitability. Persistent negative EBIT and net margins suggest the business has not yet achieved scalable clinic economics, limiting internal funding for expansion and prolonging reliance on external capital.

Negative operating and free cash flow

Sustained negative operating cash flow depletes liquidity and constrains reinvestment in clinics and services. Even with improving FCF growth, negative OCF-to-income indicates operational inefficiencies that can force repeated financing, impede scale benefits, and weaken resilience to cost shocks over coming quarters.

Reliance on external financing and equity actions

Frequent capital raises and a reverse split reflect ongoing funding gaps and shareholder dilution risk. Dependence on private placements to support acquisitions and service debt implies current operations do not generate sufficient cash, creating structural financing risk if profitability and cash flows do not materially improve.

INVO Fertility Business Overview & Revenue Model

Company Description

INVO Fertility is a leading provider of in vitro fertilization (IVF) services, specializing in advanced reproductive technologies to assist individuals and couples facing fertility challenges. The company operates fertility clinics across the United States, offering a comprehensive range of services including fertility assessments, IVF procedures, egg freezing, and donor egg programs. INVO Fertility is committed to providing personalized care and innovative solutions, guided by a team of experienced reproductive endocrinologists and healthcare professionals.

How the Company Makes Money

INVO Fertility generates revenue primarily through the provision of IVF services and related fertility treatments. The company charges patients for various services including initial consultations, diagnostic tests, IVF cycles, egg retrievals, and embryo transfers. Additional revenue streams include payments for ancillary services such as sperm banking, genetic testing, and medication prescriptions. INVO Fertility may also partner with insurance companies to offer patients coverage options, which can further enhance revenue. Additionally, the company may engage in strategic partnerships with pharmaceutical companies for the supply of fertility medications, which can provide additional income through negotiated agreements.

INVO Fertility Financial Statement Overview

Summary

INVO Fertility is experiencing revenue growth, but significant challenges remain in achieving profitability and efficient cash flow management. The company has improved its leverage position, but negative returns on equity and persistent losses indicate underlying operational inefficiencies. Continued focus on cost management and operational improvements is necessary to enhance financial health.

Income Statement

INVO Fertility's income statement shows a consistent increase in revenue over the years, with a TTM revenue growth rate of 4.89%. However, the company is struggling with profitability, as indicated by negative net profit margins and EBIT margins. The gross profit margin has decreased from 96.51% in 2021 to 39.17% in TTM, reflecting increased cost pressures. Overall, the company is experiencing growth but is facing significant profitability challenges.

Balance Sheet

The balance sheet reveals a moderate debt-to-equity ratio of 0.72 in TTM, which is an improvement from previous years, indicating better leverage management. However, the return on equity remains negative, suggesting inefficiencies in generating returns on shareholder investments. The equity ratio is not explicitly calculated, but the company's equity position has been volatile, impacting financial stability.

Cash Flow

INVO Fertility's cash flow statement highlights challenges in cash generation, with negative operating and free cash flows. The free cash flow growth rate is positive at 17.27% in TTM, indicating some improvement. However, the operating cash flow to net income ratio is negative, reflecting ongoing operational inefficiencies. The free cash flow to net income ratio is slightly above 1, suggesting that cash flow is somewhat aligned with net income, despite being negative.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	6.94M	6.53M	3.02M	822.20K	4.16M	1.04M
Gross Profit	2.72M	2.87M	1.09M	-28.57K	4.02M	948.53K
EBITDA	-24.39M	-7.14M	-6.88M	-10.75M	-5.22M	-5.48M
Net Income	-28.96M	-9.10M	-8.03M	-10.89M	-6.65M	-8.35M
Balance Sheet
Total Assets	18.83M	46.45M	18.51M	3.71M	10.47M	10.95M
Cash, Cash Equivalents and Short-Term Investments	355.89K	741.40K	232.42K	90.14K	5.68M	10.10M
Total Debt	4.23M	9.90M	6.30M	2.27M	2.12M	775.02K
Total Liabilities	12.98M	33.70M	17.61M	4.69M	3.16M	5.20M
Stockholders Equity	5.85M	12.75M	892.83K	-977.61K	7.31M	5.74M
Cash Flow
Free Cash Flow	-7.77M	-3.16M	-5.20M	-6.62M	-6.48M	-4.86M
Operating Cash Flow	-7.66M	-2.97M	-4.76M	-6.60M	-6.03M	-4.78M
Investing Cash Flow	354.98K	363.89K	-2.49M	-81.22K	-2.15M	-187.25K
Financing Cash Flow	7.19M	3.12M	7.39M	1.09M	3.77M	13.82M

INVO Fertility Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.93
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IVF, the sentiment is Negative. The current price of 0.93 is above the 20-day moving average (MA) of 0.86, below the 50-day MA of 1.87, and below the 200-day MA of 17.95, indicating a bearish trend. The MACD of -0.29 indicates Negative momentum. The RSI at 32.56 is Neutral, neither overbought nor oversold. The STOCH value of 7.26 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IVF.

INVO Fertility Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
IVF	41 Neutral	$1.94M	>-0.01	-922.88%	―	11.50%	2.37%

INVO Fertility Corporate Events

INVO Fertility realigns leadership to accelerate clinic growth

On December 30, 2025, INVO Fertility announced a realignment of its executive leadership team to better support its growth strategy centered on acquiring and establishing fertility clinics and related businesses. Company controller Terah Krigsvold, with the firm since 2020, was promoted to chief financial officer, succeeding Andrea Goren, who moved into the roles of chief business officer and chief executive officer of INVO Centers LLC, the subsidiary overseeing fertility clinics. Management emphasized that the changes are intended to maintain continuity in finance while freeing Goren to leverage his experience in financing and acquisition transactions to drive clinic acquisitions, new clinic launches, and related legal, diligence, and investor-relations activities, underscoring a sharper operational focus on scaling the clinic network and moving the business toward profitability.

The most recent analyst rating on (IVF) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on INVO Fertility stock, see the IVF Stock Forecast page.

INVO Fertility signs agreement to acquire assets

INVO Fertility, Inc. has signed a definitive agreement to acquire the non-clinical assets of Family Beginnings, a well-regarded fertility clinic in Indianapolis, Indiana, for $750,000. The acquisition is expected to close by February 27, 2026, subject to conditions such as regulatory approvals. This deal reflects INVO’s strategic plan to grow its network of fertility centers across the U.S. and enhance its offerings by integrating Family Beginnings’ well-established services, which generated $1.2 million in revenue over the past year. Dr. James Donahue, the clinic’s owner and medical director, will continue leading the clinic under a three-year contract. The acquisition aligns with INVO’s mission to improve access to fertility care and could strengthen its market position as a leading provider of innovative ART solutions.

The most recent analyst rating on (IVF) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on INVO Fertility stock, see the IVF Stock Forecast page.

INVO Fertility Announces $4M Private Placement Agreement

On December 2, 2025, INVO Fertility, Inc. announced a securities purchase agreement with an institutional investor to raise approximately $4 million through a private placement. The company plans to use the proceeds to fund the acquisition of Family Beginnings, P.C., pay down debt, and for general corporate purposes. This strategic move is expected to enhance INVO Fertility’s market positioning by expanding its clinic operations and improving financial stability. The offering, facilitated by Maxim Group LLC, is set to close on December 3, 2025, subject to customary conditions.

The most recent analyst rating on (IVF) stock is a Sell with a $1.50 price target. To see the full list of analyst forecasts on INVO Fertility stock, see the IVF Stock Forecast page.

INVO Fertility Implements Reverse Stock Split

On November 26, 2025, INVO Fertility filed a Certificate of Change to implement a 1-for-8 reverse stock split of its common stock, which became effective on November 28, 2025. This adjustment reduced the number of issued and outstanding shares and proportionately adjusted authorized shares, stock options, and warrants. The company’s stock continues to trade on Nasdaq under the symbol ‘IVF’ with a new CUSIP number. This strategic move is expected to impact the company’s market positioning by potentially increasing the stock’s market value and attracting more investors.

The most recent analyst rating on (IVF) stock is a Sell with a $1.50 price target. To see the full list of analyst forecasts on INVO Fertility stock, see the IVF Stock Forecast page.

INVO Fertility Investor Exercises Additional Investment Right

On October 16, 2025, an institutional investor of INVO Fertility exercised its Additional Investment Right to acquire 500 shares of Series C-2 Convertible Preferred Stock for $500,000. This transaction adjusted the conversion price to $0.6285 per share and was conducted without registration under the Securities Act, impacting the company’s financial structure and shareholder composition.

The most recent analyst rating on (IVF) stock is a Hold with a $0.50 price target. To see the full list of analyst forecasts on INVO Fertility stock, see the IVF Stock Forecast page.